NK Cell Depletion, IL-18 Therapy, and IFN-γ Blockade

For NK cell depletion, mice were injected IP with 100 μg anti-NK1.1 (PK136, BioXcell, BE0036) or isotype control (C1.18.4, BioXCell, BE0085). Depletion of NK1.1-positive cells was confirmed by flow cytometry. For IL-18 therapies, mice were injected IP with 0.2 μg recombinant mouse IL-18 (rmIL-18; MBL) at the time of infection, and daily until harvest as we previously described^{23 (link)}. For ASM depletion, mice were injected IP with 10mg/kg/mouse of imipramine (Sigma) or PBS control beginning at day −1 prior to infection, then daily. For in vivo IFN-γ blockade, mice were injected IP with 500 μg/mouse of anti-mouse IFN-γ (XMG1.2, BioXcell, BE0055) or isotype (Rat IgG1, BioXcell BE0290) control beginning at day −1 prior to infection, then every other day.